Amgen Faces Pressure as Biosimilar Competition Intensifies
PILLAR DIAGNOSTIC // WEEK 10
“Accelerating biosimilar and generic competition across Amgen’s core franchises is colliding with near-term growth expectations, and institutional selling suggests the market is already repricing ahead of broader sentiment adjustment.”
Proposed action
Tactical short (fade rallies)
THE MECHANICS
Tape & flow
Selling pressure in the tape dragged Dow blue-chips lower, with Amgen shares plunging over 3%.
THE MACHINE
Operational momentum
Revenue grew 8.6% to $9.87 billion last quarter and 14.2% annually over the past two years, with adjusted EPS of $5.29 beating estimates even as current‐quarter earnings are expected to dip 2.2% year-over-year and sales forecast to rise about 4.9%. Robust free cash flow funded a $2.52-per-share quarterly dividend and a $3.96 billion bond issuance to support internal development, bolt-on acquisitions or partnerships. Biosimilar launches in 2024–25 expand marketed offerings, and the weight-loss candidate MariTide has advanced into Phase 3.
THE MAP
Structure & constraints
Key Amgen franchises like Prolia, Xgeva, and Otezla face global biosimilar and generic launches driving accelerated sales erosion by 2026, even as MariTide advances through phase 3 toward potential approval within three years and Amgen expands its competitive pipeline across obesity, oncology biosimilars, cardiovascular, and chronic kidney disease therapies, necessitating strategic R&D reallocation amidst a crowded therapeutic landscape.
THE MOOD
Consensus & positioning
Diversified late-stage portfolio underpins investor confidence around limited downside from weight-loss exposure, yet safety-driven trial halts and anticipated seasonal sales dips have injected caution, driving focus on R&D reallocation and contrasting bullish vs bearish fair-value narratives.
